Push­ing mR­NA ther­a­peu­tics for can­cer, Cam­bridge start­up nabs Se­ries A to ex­plore next-gen ap­proach

With in­creased in­ter­est in mR­NA ther­a­peu­tics thanks to Pfiz­er and Mod­er­na’s megablock­buster Covid-19 vac­cines, a new start­up lo­cat­ed next to MIT is get­ting in­fused with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER